CNAT Conatus Pharmaceuticals Inc

Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member

Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member

SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional independent member.

“We are pleased to expand the perspective of our Board of Directors with the addition of a proven financial leader with substantial experience in strategic transactions, corporate governance and financial reporting,” said Steven J. Mento, Ph.D., President, Chief Executive Officer and co-founder of Conatus. “Kathy’s demonstrated capabilities across a broad range of life science finance initiatives should prove most helpful to Conatus as we continue with Oppenheimer & Co., Inc., in our review of strategic alternatives.”

Kathleen Scott

Ms. Scott is currently a Managing Director at Hale BioPharma Ventures, and Chief Financial Officer for some of its portfolio companies in the life science industry including Adigica Health, an e-commerce company focused on selling health care products direct to the consumer; Recros Medica, a development stage company designing a medical device to be used by plastic surgeons and dermatologists for skin tightening; and Neurana Pharmaceuticals, a specialty pharmaceutical company developing therapeutic products to treat unmet needs in diseases and conditions of the central nervous system. Ms. Scott also was previously the Chief Financial Officer of Oncternal Therapeutics, Clarify Medical and MDRejuvena.

Ms. Scott has over 25 years of experience in finance, accounting, M&A, and restructurings for public and private companies. Previously Ms. Scott was a Partner at RA Capital Advisors, a San Diego private investment bank providing financial advisory services. She spent over 15 years with RA Capital Advisors, completing billions of dollars of mergers, acquisitions, divestitures, and restructurings for a broad range of corporate clients. Ms. Scott started her career as an auditor in Arthur Andersen’s San Diego office, focusing on both public and private clients. Ms. Scott is a CPA and CFA charter holder. She is currently chair of the board of directors of the YMCA of San Diego County and a board member of Corporate Directors’ Forum.

CONTACT: Keith Marshall

Conatus Pharmaceuticals Inc.

(858) 376-2600

EN
18/11/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Conatus Pharmaceuticals Inc

 PRESS RELEASE

Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuti...

Leading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock Split SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that Institutional Shareholder Services Inc. (ISS) and Glass Lewis, two leading independent research and proxy advisory firms that provide institutional investors with voting assessment and recommendations, have recommended that Conatus stockholders vote “FOR” Conatus’ proposed merger with Histogen Inc. (“Histogen”) and “FO...

 PRESS RELEASE

Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived material for spinal disc repair in the Journal of Medicine and Surgical Sciences. Histogen has developed a cell conditioned media (CCM) that is embryonic-like in composition and that has been shown to stimulate stem cells in vivo. The material expresses stem cell-...

 PRESS RELEASE

Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of...

Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for HST 001, the Company’s lead therapeutic candidate for the treatment of androgenic alopecia in men. Under this IND, Histogen intends to initiate a Phase 1b/2a clinical trial of HST 001, a H...

 PRESS RELEASE

The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Ap...

The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020 SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today convened and adjourned its special meeting of stockholders in order to obtain a quorum and specific stockholder approvals required pursuant to the terms of its merger agreement with Histogen Inc. Conatus announced it needs additional time to solicit stockholder votes in order to obtain a quorum for the meeting and affirmative votes from a majority of t...

 PRESS RELEASE

Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results a...

Conatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process Update SAN DIEGO, May 01, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2020 and provided an update on its strategic process. Recent Developments In January 2020, Conatus announced that it had entered into a definitive agreement with Histogen Inc., a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, under which Histogen will mer...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch